Michael Binder, MD
Plastic and Reconstructive Surgery · Willoughby, OHNPI 1922198357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Smith+Nephew at 53.2% of the total. Reporting peaked in 2022 at $592 and has fallen 55.1% since, to $266 in 2024.
Across 65 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$1K
- Organogenesis Inc.$460
- Convatec Inc.$129
- Melinta Therapeutics, LLC$107
- Kerecis Limited$87
- AbbVie$38
- plus $150 from 8 others
What the payments were for
- Travel & lodging$281%
- Food & beverage$2,05199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 31 | $1,107 |
| Organogenesis Inc. | 15 | $460 |
| Convatec Inc. | 2 | $129 |
| Melinta Therapeutics, LLC | 5 | $107 |
| Kerecis Limited | 2 | $87 |
| AbbVie | 2 | $38 |
| Johnson & Johnson | 1 | $27 |
| Integra Lifesciences Corporation | 1 | $24 |
| Next Science LLC | 1 | $22 |
| Cashflow Solutions, LLC | 1 | $18 |
| KCI USA, Inc. | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| ADMA Biomanufacturing LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GRAFIX PL$332
- RENASYS GO v2 HOME$124
- Grafix$121
- Grafix XC$121
- AQUACEL AG$110
- REGRANEX$108
How this compares
$2,079 in reported general payments places this provider in the 55th percentile of 78 plastic and reconstructive surgery providers in Ohio.
See all plastic and reconstructive surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 40 | $384 |
| Silver Sulfadiazine | 11 | $213 |
| Ciprofloxacin Hcl | 21 | $170 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $90 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Willoughby
- Paul VanekMentor$91K
- Richard SimmanToledo$76K
- Sunishka WimalawansaBeavercreek$68K
- James GatherwrightCleveland$52K
- Matthew GoldschmidtIndependence$47K
- Katherine GrawePowell$44K
- Abeer KalandarCleveland$34K
- David MegeeCincinnati$25K
- William AbouhassanColumbus$19K
- Todd HicksDayton$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.